Metformin has been the cornerstone of Type 2 diabetes treatment for over 60 years. With newer, more glamorous medications capturing headlines, it is worth examining what metformin still does exceptionally well — and where its limitations lie.
Why Metformin Has Remained First-Line
The landmark UKPDS demonstrated that metformin reduces cardiovascular mortality in overweight people with Type 2 diabetes. It is also the only oral diabetes medication with evidence of cancer risk reduction. Its practical advantages: inexpensive, widely available, does not cause hypoglycaemia when used alone, and has a well-understood safety profile built over decades.
Metformin vs Newer Medications
| Factor | Metformin | SGLT2 Inhibitors | GLP-1 Agonists |
|---|---|---|---|
| HbA1c reduction | 1.0–1.5% | 0.5–1.0% | 1.0–2.0% |
| Weight effect | Neutral/slight loss | Modest loss (2–3kg) | Significant loss (4–15kg) |
| Cost | Very low | High | Very high |
✅ Key Takeaway
Metformin remains an excellent first-line treatment for most people with Type 2 diabetes, offering proven cardiovascular benefits, a strong safety record, and very low cost. The best treatment plan is always individualised — discuss your options with your healthcare team.
Urdu 
English